异烟肼和利福平耐药突变与二线药物耐药及痰培养转阴的关联
该多国前瞻性队列研究纳入2005至2008年7国447例耐多药结核患者,用Hain MTBDRplus检测inhA、katG和rpoB突变。发现rpoB D516V较S531L对利福布丁交叉耐药少但基线其他药物耐药多、获得性氟喹诺酮耐药增加;inhA启动子加katG突变较单纯katG突变基线XDR多、获得性氟喹诺酮耐药增加且痰培养转阴更慢(125.5 vs 89.0天)。
要点
- rpoB D516V较S531L对利福布丁交叉耐药少,但基线其他药物耐药和获得性氟喹诺酮耐药增加。
- inhA启动子加katG突变较单纯katG突变基线XDR更多、获得性氟喹诺酮耐药增加。
- inhA启动子加katG突变者痰培养转阴更慢(125.5 vs 89.0天)。
核心结论
- inhA和katG特定突变与其它药物耐药差异及痰培养转阴时间相关。
- 分子检测可能有助于按突变谱定制治疗并评估额外耐药风险。
研究设计与样本
- 多国前瞻性队列研究,纳入2005年1月至2008年12月7国447例耐多药结核参与者。
- 用Hain MTBDRplus线性探针检测痰分离株inhA、katG和rpoB突变。
- 对特定突变行双变量分析确定基线或获得性其他结核药物相对风险。
- 用Kaplan-Meier曲线和分层Cox回归比较痰培养转阴时间(TSCC)。
主要发现
- 相对rpoB S531L,rpoB D516V分离株对利福布丁交叉耐药较少、基线其他药物耐药增加、获得性氟喹诺酮耐药增加。
- 相对单纯katG突变,inhA启动子加katG突变与基线广泛耐药结核(XDR)、获得性氟喹诺酮耐药增加相关。
- inhA启动子加katG突变者TSCC更慢(125.5 vs 89.0天)。
临床怎么用
- 对耐多药结核可依据inhA、katG和rpoB特定突变谱评估其他药物耐药风险。
- inhA启动子加katG突变者可能需关注更慢的痰培养转阴和获得性氟喹诺酮耐药。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Mutations in the genes inhA, katG, and rpoB confer resistance to anti-tuberculosis (TB) drugs isoniazid and rifampin. We questioned whether specific mutations in these genes were associated with different clinical and microbiological characteristics. METHODS: In a multicountry prospective cohort study of multidrug-resistant TB, we identified inhA, katG, and rpoB mutations in sputum isolates using the Hain MTBDRplus line probe assay. For specific mutations, we performed bivariate analysis to determine relative risk of baseline or acquired resistance to other TB drugs. We compared time to sputum culture conversion (TSCC) using Kaplan-Meier curves and stratified Cox regression. RESULTS: In total, 447 participants enrolled from January 2005 to December 2008 from 7 countries were included. Relative to rpoB S531L, isolates with rpoB D516V had less cross-resistance to rifabutin, increased baseline resistance to other drugs, and increased acquired fluoroquinolone resistance. Relative to mutation of katG only, mutation of inhA promoter and katG was associated with baseline extensively drug resistant (XDR) TB, increased acquired fluoroquinolone resistance, and slower TSCC (125.5 vs 89.0 days). CONCLUSIONS: Specific mutations in inhA and katG are associated with differences in resistance to other drugs and TSCC. Molecular testing may make it possible to tailor treatment and assess additional drug resistance risk according to specific mutation profile.
引用
- Click ES, Kurbatova EV, Alexander H, et al. Isoniazid and Rifampin-Resistance Mutations Associated With Resistance to Second-Line Drugs and With Sputum Culture Conversion. J Infect Dis. 2020. PMID: 32002554. doi:10.1093/infdis/jiaa042
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。